mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah Cannon Research Institute phase I trial.
L. Hart
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
J. R. Infante
Consultant or Advisory Role - Novartis
S. F. Jones
No relevant relationships to disclose
D. R. Spigel
Consultant or Advisory Role - Novartis (U)
J. C. Bendell
No relevant relationships to disclose